Explore 3 Stock Ideas & Industry Insights Download Free Report

News

enVVeno Medical (NASDAQ:NVNO): How Close Is Its First-of-a-Kind Venous Valve to Pivotal Trials?

● enVVeno reported second-quarter 2026 financial results and advances toward an FDA pivotal trial for its first-in-class replacement venous valve.

Vinay Lochav | 27 August 2026

Phreesia (NYSE:PHR): What Does Crossing Into Profitability Mean Next?

Phreesia (NYSE:PHR), a healthcare-technology company that helps medical practices manage patient intake, scheduling and payments, has reached an important milestone: profitability. After years of prioritizing growth, the company crossed into positiveNet Incomewhile continuing to expand revenue.

Vinay Lochav | 27 August 2026

ADC Therapeutics (NYSE:ADCT): Can Cost Discipline and Label Expansion Offset Trial Uncertainty?

ADC Therapeutics (NYSE:ADCT) is working to build on its approved lymphoma treatment while advancing a pipeline of antibody-drug conjugates. The company reported second-quarter 2026 results that narrowed its loss, though questions around a key confirmatory study tempered the picture.

Vinay Lochav | 27 August 2026

Atossa Therapeutics (NASDAQ:ATOS): What Could Reverse Its Recent Setbacks?

Atossa Therapeutics (NASDAQ:ATOS) is advancing a differentiated approach to breast-cancer treatment and prevention. The company is building a body of evidence for its lead candidate across multiple settings, with the path forward running through clinical data and regulatory progress.

Vinay Lochav | 27 August 2026

Cadrenal Therapeutics (NASDAQ:CVKD) Quietly Strengthens: Why the Stock Deserves a Fresh Look

●Pediatric designation plans:On June 18, 2026, Cadrenal announced plans to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease.

Vinay Lochav | 27 August 2026

Filana Therapeutics (NASDAQ:FLNA): Can a Rebrand From Cassava Sciences Rebuild Investor Trust?

● The company's lead drug simufilam failed to demonstrate benefit in Alzheimer's disease trials.

Vinay Lochav | 27 August 2026

Leggett & Platt CEO Reports Merger-Driven Ownership Changes

Karl G. Glassman, President and CEO of Leggett & Platt Inc., filed a Form 4 on August 27, 2026, disclosing multiple changes in beneficial ownership of common stock and derivative securities resulting from the company's merger with Somnigroup International Inc.

Manish Choudhary | 27 August 2026

Leggett & Platt EVP Reports Merger-Driven Ownership Changes

James Tyson Hagale, Executive Vice President and President of Bedding Products at Leggett & Platt Inc (NYSE:LEG), filed a Form 4 on August 27, 2026, reporting changes in beneficial ownership resulting from the company's merger with Somnigroup International Inc.

Shwetambri Chauhan | 27 August 2026

Leggett & Platt EVP Reports Merger-Driven Share Changes

Ryan Michael Kleiboeker, EVP and Chief Strategic Planning Officer of Leggett & Platt Inc, filed a Form 4 on August 27, 2026, disclosing multiple changes in beneficial ownership resulting from the company's merger with Somnigroup International Inc., effective August 26, 2026.

Aditi Sarkar | 27 August 2026

Church & Dwight EVP Exercises Options, Sells 15,375 Shares

Carlos G. Linares, EVP Chief Tech & Global New Product Officer at Church & Dwight Co Inc /DE/ (NYSE:CHD), filed a Form 4 on August 27, 2026, reporting the exercise of stock options and a same-day sale of common stock on August 26, 2026.

Aditi Sarkar | 27 August 2026
Support

Hi! How can we help you today?

Loading…